ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 52 citations in OpenAlex.
- The glycobiology of prostate cancer: an update.Oncogene · 2026Review
- Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation.Signal transduction and targeted therapy · 2026Review
- Defining the combinatorial nature of gene modules in prostate cancer underlying lineage plasticity and metastasis.Research square · 2026Article
- A single-cell and spatial atlas of prostate cancer reveals the combinatorial nature of gene modules underlying lineage plasticity and metastasis.bioRxiv : the preprint server for biology · 2026Article
- ODC1 Polyamine Metabolism Drives Prostate Cancer via AKT and Splicing.Journal of cellular and molecular medicine · 2026Article
- miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC.Biomarker research · 2026Article
- Molecular profiling of ex vivo prostate cancer CAF models captures stromal heterogeneity and drug vulnerabilities.Cell death discovery · 2025Article
- The Immunomodulatory Role of Galectin-1 in the Tumour Microenvironment and Strategies for Therapeutic Applications.Cancers · 2025Review
- Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy.Biomarker research · 2025Review
- Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy - obstacles and perspectives.Transcription · 2025Review
- Inhibition of Galectin-1 and Androgen Receptor Axis Enhances Enzalutamide Treatment in Enzalutamide Resistant Prostate Cancer.Cancers · 2025Article
- Beyond CTLA-4 and PD-1: Novel Insights into MAO-A as a Next Generation Immune Checkpoint Modulator for Cancer Immunotherapy.Current cancer drug targets · 2025Review
- GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment.Biomarker research · 2024Article
- A novel green and efficient heterogeneous acid catalyst for the one-pot synthesis of benzopyrazine-aminoimidazole hybrids with antiproliferative potential.RSC advances · 2024Article
- Identification of prostate cancer bone metastasis related genes and potential therapy targets by bioinformatics and in vitro experiments.Journal of cellular and molecular medicine · 2024Article
- Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance.Frontiers in endocrinology · 2024Review
- Improving cancer immunotherapy in prostate cancer by modulating T cell function through targeting the galectin-1.Frontiers in immunology · 2024Article
- The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer.Scientific reports · 2023Article
- Targeting galectin-driven regulatory circuits in cancer and fibrosis.Nature reviews. Drug discovery · 2023Review
- Galectin-1: A Traditionally Immunosuppressive Protein Displays Context-Dependent Capacities.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 4 countries.
Tsung-Chieh ShihDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California.
Ruiwu LiuDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California. kslam@ucdavis.edu rwliu@ucdavis.edu.
Chun-Te WuDepartment of Urology, Chang Gung Memorial Hospital, Keelung, Taiwan.
Xiaocen LiDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California.
Wenwu XiaoDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California.
Xiaojun DengDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California.
Sophie KissDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California.
Ting WangGenome Center, University of California, Davis, Davis, California.
Xiao-Jia ChenInstitute of Biomedicine & Cell Biology Department, Jinan University, Guangzhou, China.
Randy CarneyDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California.ORCID 0000-0001-8193-1664
Hsing-Jien KungThe Institute for Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan.
Yong DuanGenome Center, University of California, Davis, Davis, California.
Paramita M GhoshDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California.
Kit S LamDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California. kslam@ucdavis.edu rwliu@ucdavis.edu.
University of California, Davis · USJinan University · CNKeelung Chang Gung Memorial Hospital · TWTaipei Medical University · TWVA Northern California Health Care System · US
Funding
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9MAMBER force field consortium: a coherent biomolecular simulation platformR01GM079383 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CIEPLAK, PIOTR, DUAN, YONG · 2007 to 2017
$4.7M(PQD-1) Selective pressure of antiandrogens on castration resistant prostate cancR01CA185509 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GHOSH, PARAMITA M. · 2014 to 2017
$1.0MDiscovery of Death Ligands Against CancersR33CA160132 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2012 to 2014
$1.0MLoss of Filamin A Nuclear Localization in Prostate Cancer ProgressionI01BX000400 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI GHOSH, PARAMITA M. · 2011 to 2019
–BLRD VA I01 BX000400NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA185509NCI NIH HHS R33 CA160132NIGMS NIH HHS R01 GM079383
Abstract
PubMed holds no abstract for this paper.
Indexed as
Androgen AntagonistsAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionGalectin 1Gene Expression Regulation, NeoplasticHumansMaleMiceNeoplasm InvasivenessNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantReceptors, AndrogenTissue Array AnalysisAndrogen AntagonistsAR protein, humanGalectin 1Receptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.